Can a new drug combo revive Immunotherapy's power against resistant tumors?
NCT ID NCT05572684
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The study includes adults with various cancer types, such as colorectal, gastric, ovarian, and lung cancer. Participants will receive both drugs intravenously, and researchers will monitor for side effects and measure tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NC410 (an experimental drug) combined with pembrolizumab (an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to standard immunotherapy.
- What could go wrong
- This is an early-phase trial, so the combination may not be safe or effective. Side effects are possible, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Oncology Associates
Tucson, Arizona, 85711, United States
-
Hackensack Meridian Health University Medical Center- John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Northwest Cancer Specialist
Vancouver, Washington, 98684, United States
-
Ochsner Cancer Institute
New Orleans, Louisiana, 70121, United States
-
Rocky Mountain Cancer Centers
Aurora, Colorado, 80012, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
St. Elizabeth Edgewood Hospital
Edgewood, Kentucky, 41017, United States
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Texas Oncology - San Antonio
San Antonio, Texas, 78240, United States
-
UT Health San Antonio
San Antonio, Texas, 78229, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75235, United States
-
University of Cincinnati Cancer Center
Cincinnati, Ohio, 45267, United States
-
Virginia Cancer Specialist
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- What raises endometrial cancer risk in black women? a study digs in